We will not end HIV as an epidemic without the expertise and leadership of Black and Latino gay and bisexual men and transgender people of color. By Jeremiah Johnson In February 2016, the CDC issued a new report with a…
Effective responses to the burgeoning hepatitis C pandemic requires solidarity between the global North and South By Bryn Gay We can now cure the hepatitis C virus (HCV) with a coformulation of drugs that yields sustained virologic responses for all…
We can’t end the viral hepatitis epidemics unless we end the war on drug users By Annette Gaudino “Unidentified Filipino male. Unidentified Filipino male. Unidentified Filipino female. Unidentified Filipino male…” It takes a long time to read 1,900 names, long…
4A case for a racial justice agenda in treatment and research By Kenyon Farrow The Tuskegee Syphilis study remains a primary citation in both the scientific literature and popular conversations to explain the reluctance of African Americans to engage with…
Upholding narratives of Black science and treatment activism, and community mobilization in HIV/AIDS and TB By Suraj Madoori In February 2016, startling data released by the Centers for Disease Control and Prevention (CDC) at the Conference of Retroviruses and Opportunistic…
Pharma’s Obligations Under the Right to Science By Erica Lessem and Brian Citro Benefitting from scientific progress is a human right, but who’s responsible for ensuring that this right is upheld? As Mike Frick clearly lays out in “Science and…
Using human rights to strengthen TB research and access By Mike Frick Editor’s note: The following is based on the transcript of a plenary address delivered by the author at TB2016, a two-day TB conference held before the July International…
By Tim Horn Maximizing HIV, tuberculosis (TB), and viral hepatitis outcomes depends on the availability of state-of-the-art diagnostic and prognostic tools, engagement in expert and supportive care, and access to safe and effective drugs. Numerous technical barriers to these core…
Generic treatments for HIV, viral hepatitis, and cancer can be affordably—and profitably—mass-produced for broad, unobstructed availability By Tracy Swan TAG talks with Andrew Hill, senior visiting research fellow in the University of Liverpool’s Department of Pharmacology, about his group’s work…